dcsimg Aranesp® (darbepoetin alfa) – Hemoglobin (Hb) Trends
› Email› Print

The nephrology landscape continues to evolve1
Hemoglobin (Hb) levels declined from 2011 to 20142

Hemoglobin (Hb) levels declined from 2011 to 2014

Aranesp® median weekly dose declined from January 2010 to December 20113

Aranesp® median weekly dose declined from January 2010 to December 2011

For patients with CKD on dialysis

  • Initiate Aranesp® treatment when the Hb level is < 10 g/dL.
  • Individualize dosing and use the lowest dose of Aranesp® sufficient to reduce the need for RBC transfusions.
  • Aranesp® is not indicated as a substitute for RBC transfusions in patients who require immediate correction of anemia.

Important Safety Information

WARNING - Chronic Kidney Disease:

  • In controlled trials, patients experienced greater risks for death, serious adverse cardiovascular reactions, and stroke when administered erythropoiesis-stimulating agents (ESAs) to target a hemoglobin level of greater than 11 g/dL.
  • No trial has identified a hemoglobin target level, Aranesp® dose, or dosing strategy that does not increase these risks.
  • Use the lowest Aranesp® dose sufficient to reduce the need for red blood cell (RBC) transfusions.

Scroll down for additional
Important Safety Information.

Abbreviations and References:
ESA = erythropoiesis-stimulating agent; Hb = hemoglobin; RBC = red blood cell.
References: 1. Fuller DS, Pisoni RL, Bieber BA, Gillespie BW, Robinson BM. The DOPPS practice monitor for US dialysis care: trends through December 2011 [published online ahead of print November 5, 2012]. Am J Kidney Dis. doi:10.1053/j.ajkd.2012.10.002. 2. Data on file. Amgen; [OutcomesPlus database; July 2014]. 3. Data on file. Amgen; [Hospital-Based Dialysis Center Electronic Medical Record (EMR) system].

Biotechnology by Amgen®